Skip to content
OpenCapital
Get started

Viridian Therapeutics, Inc. VRDN Derivative Liabilities (Non-Current)

Derivative Liabilities (Non-Current) at other companies

PVL
Palvella TherapeuticsPVLA
$2.16M+25.3%

Other financials

Income statement

See full
Revenue$141.0K+95.8%
Operating income-$116.2M-23.8%
Net income-$104.9M-20.7%
EPS (diluted)-$1.15-5.5%

Balance sheet

See full
Cash & equivalents$176.3M+51.7%
Total debt$36.8M+59.4%
Total equity$636.0M+5.2%
Total assets$789.0M+19.4%

Cash flow

See full
Operating cash flow-$119.7M-29.1%
CapEx$23.0K-73.3%
Free cash flow-$119.7M-29.0%

Valuation

See full
Market cap$1.91B+82.0%

Profitability

See full
Gross margin36.3%—
Operating margin-543.9%-271pp
Net margin-508.5%-254pp
FCF margin-428.4%-214pp

Returns & leverage

See full
Return on equity-58.1%+7.9pp
Debt / equity0.1×0.0×
Current ratio15.1×-4.3×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesNoncurrent.

The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viridian Therapeutics, Inc.'s derivative liabilities (non-current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viridian Therapeutics, Inc.'s derivative liabilities (non-current)?
Viridian Therapeutics, Inc. (VRDN) reported derivative liabilities (non-current) of $12.5M in Q1 2026.
What does derivative liabilities (non-current) mean?
This metric represents the fair value of derivative financial instruments classified as long-term liabilities that are not expected to be settled within the next twelve months. These instruments often arise from complex financing arrangements, such as warrants or embedded conversion features in debt, and reflect potential future obligations that do not require immediate cash outflows. Monitoring this balance is essential for assessing long-term financial risk and the potential for future equity dilution or cash settlement obligations.